Annals of the Rheumatic Diseases最新文献

筛选
英文 中文
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-02-01 DOI: 10.1016/j.ard.2025.01.014
Qingran Yan, Cosimo Bruni, Alexandru Garaiman, Carina Mihai, Suzana Jordan, Mike Oliver Becker, Muriel Elhai, Rucsandra Dobrota, Petelytska Liubov, Joerg Henes, Eric Hachulla, Elise Siegert, Alexandra Balbir-Gurman, Giovanna Cuomo, Gabriela Riemekasten, Stefan Heitmann, Davide Mohammad Reza Beigi, Susanne Ullman, Petros Sfikakis, Francesca Ingegnoli, Vera Bernardino, Marie-Elise Truchetet, Madelon Vonk, Francesco Del Galdo, Anna-Maria Hoffmann-Vold, Ye Shuang, Oliver Distler
{"title":"Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.","authors":"Qingran Yan, Cosimo Bruni, Alexandru Garaiman, Carina Mihai, Suzana Jordan, Mike Oliver Becker, Muriel Elhai, Rucsandra Dobrota, Petelytska Liubov, Joerg Henes, Eric Hachulla, Elise Siegert, Alexandra Balbir-Gurman, Giovanna Cuomo, Gabriela Riemekasten, Stefan Heitmann, Davide Mohammad Reza Beigi, Susanne Ullman, Petros Sfikakis, Francesca Ingegnoli, Vera Bernardino, Marie-Elise Truchetet, Madelon Vonk, Francesco Del Galdo, Anna-Maria Hoffmann-Vold, Ye Shuang, Oliver Distler","doi":"10.1016/j.ard.2025.01.014","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.014","url":null,"abstract":"<p><strong>Objectives: </strong>Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) most frequently used for systemic sclerosis-associated interstitial lung disease (SSc-ILD). This post hoc study aimed to compare their effectiveness in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database.</p><p><strong>Methods: </strong>We included radiologically confirmed SSc-ILD patients with treatment records for TCZ, RTX, MMF, or CYC. The primary endpoint was the change in forced vital capacity (FVC) percent predicted from baseline to follow-up. Analyses were adjusted for clinical and demographic characteristics, cotreatments, and follow-up duration using propensity score-based inverse probability of treatment weighting (IPTW).</p><p><strong>Results: </strong>Nine hundred fifty-five patients with 997 treatment observations were included in the study. The median follow-up time was 11 months (IQR, 8-14 months). After IPTW, the changes in FVC percent predicted were not significantly different in the multigroup comparison (P = .101). Paired comparisons showed no significant difference. CYC was associated with stable FVC in logistic regression. For subgroup analysis, the treatment differences in change of FVC percent predicted among the 4 groups were not significant in patients with combination IS or previous exposure to TCZ, RTX, or conventional IS, as well as in current smokers or nonsmokers, and regardless of whether observations started either at the initiating or noninitiating stage of the treatment.</p><p><strong>Conclusions: </strong>In this first large real-world study, the effectiveness of TCZ, RTX, MMF, and CYC on FVC change in SSc-ILD patients was not statistically different.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-02-01 DOI: 10.1016/j.ard.2025.01.025
Zahi Touma, Ian N Bruce, Richard Furie, Eric Morand, Raj Tummala, Shelly Chandran, Gabriel Abreu, Jacob Knagenhjelm, Kellyn Arnold, Hopin Lee, Eleanor Ralphs, Aleksandr Bedenkov, Danuta Kielar, Miina Waratani
{"title":"Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls.","authors":"Zahi Touma, Ian N Bruce, Richard Furie, Eric Morand, Raj Tummala, Shelly Chandran, Gabriel Abreu, Jacob Knagenhjelm, Kellyn Arnold, Hopin Lee, Eleanor Ralphs, Aleksandr Bedenkov, Danuta Kielar, Miina Waratani","doi":"10.1016/j.ard.2025.01.025","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.025","url":null,"abstract":"<p><strong>Objectives: </strong>Anifrolumab is approved for the treatment of systemic lupus erythematosus (SLE). We aimed to determine if anifrolumab plus standard of care (SOC) was associated with reduced organ damage accumulation in adult patients with moderately to severely active SLE compared to real-world (RW) external controls from the University of Toronto Lupus Clinic (UTLC) cohort who received SOC only.</p><p><strong>Methods: </strong>Patients who initiated 300 mg anifrolumab in the TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) trials were included in the anifrolumab arm; key eligibility criteria were applied to the UTLC to create the RW SOC arm. Propensity score and censoring weighting were used to account for baseline confounding and loss to follow-up. The primary endpoint was change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score from baseline to week 208, and the secondary endpoint was time to first SDI score increase.</p><p><strong>Results: </strong>354 patients were included in the anifrolumab arm, and 561 patients were included in the RW SOC arm. Following weighting, mean change in SDI was 0.416 points lower (95% CI: -0.582, -0.249; P < .001) in the anifrolumab arm than in the RW SOC arm. Patients in the anifrolumab arm were 59.9% less likely (hazard ratio: 0.401; 95% CI: 0.213, 0.753, P = .005) to experience an increase in SDI within 208 weeks.</p><p><strong>Conclusions: </strong>Patients who received anifrolumab accumulated significantly less organ damage after 208 weeks than patients who received RW SOC. The addition of anifrolumab to SOC is effective at preventing and/or delaying organ damage in patients with moderately to severely active SLE.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1136/ard-2024-225732
Eleni Tiniakou, Alex Girgis, Tiara Siafei, Jemima Albayda, Brittany Adler, Julie J Paik, Christopher A Mecoli, Alison Rebman, Mark J Soloski, Lisa Christopher-Stine, Kellie N Smith, Antony Rosen, Andrew Lee Mammen, Erika Darrah
{"title":"Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.","authors":"Eleni Tiniakou, Alex Girgis, Tiara Siafei, Jemima Albayda, Brittany Adler, Julie J Paik, Christopher A Mecoli, Alison Rebman, Mark J Soloski, Lisa Christopher-Stine, Kellie N Smith, Antony Rosen, Andrew Lee Mammen, Erika Darrah","doi":"10.1136/ard-2024-225732","DOIUrl":"10.1136/ard-2024-225732","url":null,"abstract":"<p><strong>Background: </strong>Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune-mediated necrotising myopathy (IMNM) is characterised by the presence of IgG autoantibodies against HMGCR and a strong association with specific HLA-DR alleles. Although these findings implicate HMGCR-specific CD4<sup>+</sup>T-cells in the disease's pathogenesis, no such cells have been described. In this study, we aimed to identify and characterise HMGCR-reactive CD4<sup>+</sup>T-cells and assess their presence in affected muscle tissue from patients with anti-HMGCR+IMNM.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells from patients with anti-HMGCR+IMNM (n=10) and dermatomyositis (DM; n=10) were stimulated with HMGCR protein and peptides identified using a natural antigen processing assay (NAPA; n=6). CD4<sup>+</sup>T-cell activation was assessed by CD154 upregulation via flow cytometry. T-cell receptor β(TCR) sequencing was performed on paired HMGCR-reactive T-cells and muscle biopsy tissue (n=5).</p><p><strong>Results: </strong>CD4<sup>+</sup>T-cell responses to HMGCR protein were higher in patients with anti-HMGCR+IMNM compared with DM (median 0.06 vs 0.00, p=0.0059). These responses were enriched in Th1-Th17 cells, and when present, they positively correlated with anti-HMGCR antibody levels (r<sup>2</sup>=0.89, p=0.0012). NAPA revealed convergent presentation of seven HMGCR core peptides, with substantial overlap in the peptide repertoires between patients. These HMGCR peptides elicited robust CD4<sup>+</sup>T-cell responses, with 9/10 anti-HMGCR+IMNM patients responding to at least one peptide, compared with 1/10 DM (p=0.0003). Analysis of HMGCR-reactive TCRs β yielded antigen-reactive motifs that were enriched in muscle biopsies (projection score 0.03 vs 0.63, p=0.007).</p><p><strong>Conclusion: </strong>HMGCR-antigen-reactive CD4<sup>+</sup>T-cells are present in the circulation and target tissue of patients with anti-HMGCR+IMNM, suggesting an active role for these cells in the pathogenesis of anti-HMGCR+IMNM.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"84 2","pages":"307-318"},"PeriodicalIF":20.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1136/ard-2024-226446
Elizabeth Winter, Olaf Dekkers, Caroline Andreasen, Salvatore D'Angelo, Natasha Appelman-Dijkstra, Simone Appenzeller, Gunter Assmann, Judith Bubbear, Oana Bulaicon, Roland Chapurlat, Varvara Choida, Gavin P R Clunie, Dimitrios Daoussis, Torsten Diekhoff, Marcel Flendrie, Olivier Fogel, Roba Ghossan, Hermann Girschick, Femke van Haalen, Neveen Hamdy, Barbara Hauser, Christian Hedrich, Philip Helliwell, Kay Geert Hermann, Antonella Insalaco, Anne Grethe Jurik, Mitsumasa Kishimoto, Willem Lems, Paivi Miettunen, Burkhard Muche, Ana Navas Cañete, Natalia Palmou-Fontana, Frits Smit, James Teh, Charlotte Verroken, Kurt de Vlam, Daniel Wendling, Wei Zhou, Hans-Georg Zmierczak, Anne Leerling
{"title":"Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults.","authors":"Elizabeth Winter, Olaf Dekkers, Caroline Andreasen, Salvatore D'Angelo, Natasha Appelman-Dijkstra, Simone Appenzeller, Gunter Assmann, Judith Bubbear, Oana Bulaicon, Roland Chapurlat, Varvara Choida, Gavin P R Clunie, Dimitrios Daoussis, Torsten Diekhoff, Marcel Flendrie, Olivier Fogel, Roba Ghossan, Hermann Girschick, Femke van Haalen, Neveen Hamdy, Barbara Hauser, Christian Hedrich, Philip Helliwell, Kay Geert Hermann, Antonella Insalaco, Anne Grethe Jurik, Mitsumasa Kishimoto, Willem Lems, Paivi Miettunen, Burkhard Muche, Ana Navas Cañete, Natalia Palmou-Fontana, Frits Smit, James Teh, Charlotte Verroken, Kurt de Vlam, Daniel Wendling, Wei Zhou, Hans-Georg Zmierczak, Anne Leerling","doi":"10.1136/ard-2024-226446","DOIUrl":"10.1136/ard-2024-226446","url":null,"abstract":"<p><strong>Background: </strong>There is considerable practice variation in labelling, diagnosis and treatment of adults with sterile bone inflammation. We developed a expert consensus recommendations on the disease definition, diagnosis and treatment of this rare condition.</p><p><strong>Methods: </strong>Systematic literature review and Grading of Recommendations, Assessment, Development and Evaluations-based appraisal of evidence, two Delphi surveys and three digital and in-person consensus meetings with a multidisciplinary expert panel and patient representatives.</p><p><strong>Results: </strong>A consensus disease definition was developed and the term 'chronic non-bacterial osteitis' (CNO) is proposed to describe adults with sterile bone inflammation. For initial imaging evaluation of adults with suspected CNO, the panel recommends MRI or otherwise CT combined with nuclear imaging. Whole-body imaging at initial evaluation can be considered for diagnostic and prognostic purposes. Suggested first-line treatment in adults with active CNO includes nonsteroidal anti-inflammatory drugs/cyclooxygenase 2-inhibitors. Second-line treatment preferably consists of intravenous bisphosphonates, and otherwise tumour necrosis factor-α inhibitors. Choice between them should be individualised, considering the presence of additional inflammatory features. The panel further discusses outcome measures, follow-up and management of adverse events and complications.</p><p><strong>Conclusions and future perspectives: </strong>These expert consensus recommendations are intended to support healthcare professionals worldwide in their care for adults with CNO. They also lay the groundwork for establishing international patient registries, translational research lines and multicentre trials, all of which are urgently required.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"84 2","pages":"169-187"},"PeriodicalIF":20.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1136/ard-2024-226437
Merav Lidar, Doron Rimar, Paula David, Elad Jacoby, Ronnie Shapira-Frommer, Orit Itzhaki, Gleb Slobodin, Myriam D Stern, Iris Eshed, Tamer Sanalla, Ronit Marcus, Avichai Shimoni, Ronit Yerushalmi, Noga Shem Tov, Ivetta Danylesko, Abraham Avigdor
{"title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis.","authors":"Merav Lidar, Doron Rimar, Paula David, Elad Jacoby, Ronnie Shapira-Frommer, Orit Itzhaki, Gleb Slobodin, Myriam D Stern, Iris Eshed, Tamer Sanalla, Ronit Marcus, Avichai Shimoni, Ronit Yerushalmi, Noga Shem Tov, Ivetta Danylesko, Abraham Avigdor","doi":"10.1136/ard-2024-226437","DOIUrl":"10.1136/ard-2024-226437","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"84 2","pages":"370-372"},"PeriodicalIF":20.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory MDA-5 dermatomyositis rapidly progressive interstitial lung disease successfully treated with emapalumab.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-01-31 DOI: 10.1016/j.ard.2025.01.010
Jennifer Concepcion, Miriam Marti, Susan Vehar, Kelly Corbitt
{"title":"Refractory MDA-5 dermatomyositis rapidly progressive interstitial lung disease successfully treated with emapalumab.","authors":"Jennifer Concepcion, Miriam Marti, Susan Vehar, Kelly Corbitt","doi":"10.1016/j.ard.2025.01.010","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.010","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-01-31 DOI: 10.1016/j.ard.2024.11.005
Jeong Yeon Kim, Young Cheol Kang, Min Jung Kim, Seon Uk Kim, Hae Rim Kang, Jeong Seon Yeo, Yujin Kim, Shin-Hye Yu, Byeongwook Song, Jung Wook Hwang, Yun-Sang Lee, Jung Woo Byun, Dae Hyun Yoo, Hyun Sook Kim, Kyuboem Han, Chun-Hyung Kim, Eun Young Lee
{"title":"Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy.","authors":"Jeong Yeon Kim, Young Cheol Kang, Min Jung Kim, Seon Uk Kim, Hae Rim Kang, Jeong Seon Yeo, Yujin Kim, Shin-Hye Yu, Byeongwook Song, Jung Wook Hwang, Yun-Sang Lee, Jung Woo Byun, Dae Hyun Yoo, Hyun Sook Kim, Kyuboem Han, Chun-Hyung Kim, Eun Young Lee","doi":"10.1016/j.ard.2024.11.005","DOIUrl":"https://doi.org/10.1016/j.ard.2024.11.005","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the efficacy of mitochondrial transplantation as a therapeutic intervention for idiopathic inflammatory myopathy (IIM). This study used a comprehensive approach, incorporating both in vitro and in vivo IIM models, and conducted a first-in-human clinical trial to assess the effectiveness and safety of mitochondria isolated from human umbilical cord mesenchymal stem cells (PN-101).</p><p><strong>Methods: </strong>Mitochondria isolated from umbilical cord mesenchymal stem cells were designated as PN-101. The efficacy of PN-101 was assessed using myoblasts derived from patients with IIM and C2C12 mouse perforin/granzyme B-treated myoblasts as an in vitro IIM model. PN-101's effect on IIM was examined using C protein-induced myositis (CIM) mice as an in vivo model. The efficacy and safety of PN-101 were evaluated in a phase 1/2a clinical trial involving 9 adult patients with refractory polymyositis or dermatomyositis.</p><p><strong>Results: </strong>The myoblasts derived from patients with IIM exhibited defects in mitochondrial function and myogenesis. PN-101 transplantation enhances muscle differentiation and mitochondrial function in IIM myoblasts. PN-101 also enhanced intracellular adenosine triphosphate content, cell viability, and myogenesis in C2C12 perforin/granzyme B-treated myoblasts. In an in vivo model, PN-101 reduced myositis severity by exhibiting anti-inflammatory effects and restoring the CIM-induced metabolic shift. In a phase 1/2a prospective clinical trial involving adult patients with refractory IIM, PN-101 demonstrated no severe adverse drug reactions and showed at least minimal improvement in the International Myositis Assessment and Clinical Studies Group (IMACS)-Total Improvement Scores (TISs) compared with baseline.</p><p><strong>Conclusions: </strong>PN-101 transplantation could serve as a novel treatment for IIM by enhancing mitochondrial repair and reducing inflammation in muscle tissues.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-01-31 DOI: 10.1136/ard-2024-225981
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Maya H Buch, Gerd R Burmester, Helena M Canhão, Katerina Chatzidionysiou, Jeffrey R Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Nathanaël Sedmak, Lucía Silva-Fernández, Zoltan Szekanecz, Kim Lauper, Axel Finckh, Jacques-Eric Gottenberg
{"title":"Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.","authors":"Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, Daniel Aletaha, Johan Askling, Karolina Gente, Heidi Bertheussen, Samuel Bitoun, Ertugrul Cagri Bolek, Maya H Buch, Gerd R Burmester, Helena M Canhão, Katerina Chatzidionysiou, Jeffrey R Curtis, Francois-Xavier Danlos, Vera Guimarães, Merete Lund Hetland, Florenzo Iannone, Marie Kostine, Tue Wenzel Kragstrup, Tore K Kvien, Anne Constanze Regierer, Hendrik Schulze-Koops, Nathanaël Sedmak, Lucía Silva-Fernández, Zoltan Szekanecz, Kim Lauper, Axel Finckh, Jacques-Eric Gottenberg","doi":"10.1136/ard-2024-225981","DOIUrl":"https://doi.org/10.1136/ard-2024-225981","url":null,"abstract":"<p><strong>Background: </strong>Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer.</p><p><strong>Objectives: </strong>To perform a systematic literature review to inform a Task Force formulating EULAR points to consider on the initiation of targeted therapies in patients with IA and a history of cancer.</p><p><strong>Methods: </strong>Specific research questions were defined within the Task Force before formulating the exact research queries with a librarian. We included studies reporting a relative risk measure of patients with a history of cancer initiating a targeted therapy or a conventional synthetic disease-modifying antirheumatic drug (csDMARD), regardless of the time since diagnosis of cancer. All relevant studies included in PubMed or Embase up to 15 July 2022 were included. Two reviewers independently performed standardised article selection, data extraction, synthesis and risk of bias assessment.</p><p><strong>Results: </strong>14 published articles and one ACR abstract fulfilled the inclusion criteria. All studies were high-quality observational studies, representing a median follow-up from treatment initiation of 4.52 years among 4428 patients and 15 062 patient-years of follow-up for new or recurrent cancer. All patients had a history of cancer, most frequently solid cancer, most frequently receiving treatment for rheumatoid arthritis and most frequently treated with tumour necrosis factor-alpha inhibitors. Across these studies, the overall HR of new incident cancer or cancer recurrence was 0.90 (95% CI 0.74 to 1.10) for patients receiving a targeted therapy versus a csDMARD.</p><p><strong>Conclusion: </strong>Overall, the targeted therapies and clinical contexts covered by the included studies were not associated with an increased risk of new incident cancer or cancer recurrence as compared with csDMARDs.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-01-30 DOI: 10.1016/j.ard.2025.01.016
Eric F Morand, Ronald van Vollenhoven, Richard A Furie, Kenneth C Kalunian, Susan Manzi, Gabriel Abreu, Raj Tummala, Elizabeth A Duncan, Hussein Al-Mossawi, Catharina Lindholm
{"title":"LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.","authors":"Eric F Morand, Ronald van Vollenhoven, Richard A Furie, Kenneth C Kalunian, Susan Manzi, Gabriel Abreu, Raj Tummala, Elizabeth A Duncan, Hussein Al-Mossawi, Catharina Lindholm","doi":"10.1016/j.ard.2025.01.016","DOIUrl":"https://doi.org/10.1016/j.ard.2025.01.016","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the long-term impact of anifrolumab versus placebo on lupus low disease activity state (LLDAS) and definition of remission in systemic lupus erythematosus (DORIS) attainment in patients with systemic lupus erythematosus (SLE).</p><p><strong>Methods: </strong>This post hoc analysis included patients with moderate to severe SLE who were randomly assigned to receive intravenous anifrolumab 300 mg or placebo (once every 4 weeks) in the 52-week, phase 3 TULIP-1/TULIP-2 trials and continued with the same treatment in the 3-year long-term extension. LLDAS/DORIS rates over time were analysed using a stratified Cochran-Mantel-Haenszel approach and logistic regression. Time to first LLDAS/DORIS was estimated using Cox regression. Cumulative time and percentage of time in LLDAS/DORIS were assessed using an analysis of covariance. All P values are nominal.</p><p><strong>Results: </strong>This analysis included 369 patients (anifrolumab n = 257, placebo n = 112). After 4 years of treatment (at Week 208), 36.9% of anifrolumab-treated patients versus 17.1% of placebo-treated patients were in LLDAS (odds ratio [OR], 2.7; 95% CI, 1.3-5.5; P = .0081); 30.3% versus 18.3% were in DORIS (OR, 1.9; 95% CI, 1.0-3.9; P = .0663). Time to first LLDAS and DORIS favoured anifrolumab versus placebo (LLDAS: hazard ratio, 1.56; 95% CI, 1.18-2.09; P = .0024; DORIS: hazard ratio, 1.50; 95% CI, 1.04-2.22; P = .0373). Cumulative time in LLDAS and DORIS was greater with anifrolumab than that with placebo (P = .0004 and P = .0032, respectively).</p><p><strong>Conclusions: </strong>LLDAS and DORIS remission, which are associated with favourable outcomes such as reduced damage and mortality in patients with SLE, are attainable and sustainable treatment targets with long-term anifrolumab treatment.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TEMPORARY REMOVAL: EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO).
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2025-01-30 DOI: 10.1016/j.ard.2024.11.006
Yongdong Zhao, Melissa S Oliver, Anja Schnabel, Eveline Y Wu, Zhaoyi Wang, Achille Marino, Cassyanne L Aguiar, Jonathan D Akikusa, Ummusen Kaya Akca, Beverley Almeida, Simone Appenzeller, Erin Balay-Dustrude, Ozge Basaran, Matthew L Basiaga, Yelda Bilginer, David A Cabral, Martina Capponi, Nathan Donaldson, Bugra Han Egeli, Emily J Fox, Antonella Insalaco, Ramesh S Iyer, Annette F Jansson, Inna Kostik, Mikhail Kostik, Leonard K Kovalick, Katia Tomie Kozu, Sivia K Lapidus, Tzielan C Lee, Aleksander Lenert, Kamran Mahmood, Edoardo Marrani, Doaa Mosad Mosa, Ian Muse, Alexander Mushkin, Katherine D Nowicki, Farzana Nuruzzaman, Karen Onel, Manuela Pardeo, Trang Sophia Pham, Lauren Potts, Athimalaipet V Ramanan, Angelo Ravelli, Nathan D Rogers, Andrew W Grim, Micol Romano, Natalie Rosenwasser, Takashi Shawn Sato, Gabriele Simonini, Jennifer B Soep, Sara M Stern, Timmy Strauss, Angela Taneja Kohli, Alexander C Theos, Lori B Tucker, Leslie F Vogel, Shima Yasin, Stephen C Wong, Katerina Bouchalova, Alison M Hendry, Kevin C Cain, Hermann J Girschick, Fatma Dedeoglu, Christian M Hedrich, Ronald M Laxer, Polly J Ferguson, Raymond Naden, Seza Ozen
{"title":"TEMPORARY REMOVAL: EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO).","authors":"Yongdong Zhao, Melissa S Oliver, Anja Schnabel, Eveline Y Wu, Zhaoyi Wang, Achille Marino, Cassyanne L Aguiar, Jonathan D Akikusa, Ummusen Kaya Akca, Beverley Almeida, Simone Appenzeller, Erin Balay-Dustrude, Ozge Basaran, Matthew L Basiaga, Yelda Bilginer, David A Cabral, Martina Capponi, Nathan Donaldson, Bugra Han Egeli, Emily J Fox, Antonella Insalaco, Ramesh S Iyer, Annette F Jansson, Inna Kostik, Mikhail Kostik, Leonard K Kovalick, Katia Tomie Kozu, Sivia K Lapidus, Tzielan C Lee, Aleksander Lenert, Kamran Mahmood, Edoardo Marrani, Doaa Mosad Mosa, Ian Muse, Alexander Mushkin, Katherine D Nowicki, Farzana Nuruzzaman, Karen Onel, Manuela Pardeo, Trang Sophia Pham, Lauren Potts, Athimalaipet V Ramanan, Angelo Ravelli, Nathan D Rogers, Andrew W Grim, Micol Romano, Natalie Rosenwasser, Takashi Shawn Sato, Gabriele Simonini, Jennifer B Soep, Sara M Stern, Timmy Strauss, Angela Taneja Kohli, Alexander C Theos, Lori B Tucker, Leslie F Vogel, Shima Yasin, Stephen C Wong, Katerina Bouchalova, Alison M Hendry, Kevin C Cain, Hermann J Girschick, Fatma Dedeoglu, Christian M Hedrich, Ronald M Laxer, Polly J Ferguson, Raymond Naden, Seza Ozen","doi":"10.1016/j.ard.2024.11.006","DOIUrl":"https://doi.org/10.1016/j.ard.2024.11.006","url":null,"abstract":"<p><p>The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信